The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

Learn more about whether Enovis Corporation or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

The Downers Grove-based physical therapy clinic operator insists a low market capitalization that led to its delisting isn't a reflection of continued operating improvement.

Learn more about whether Mirion Technologies, Inc. or PAR Technology Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors ...

"Cell and gene therapy is advancing quickly, but the industry relies on older, cumbersome techniques like biosafety cabinets or tube welding for sterile processing," said Troy Ostreng, Senior Product ...

Meet Argentina’s President and his “chainsaw” minister, who say they are exporting their chainsaw deregulation model around ...

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen ...